Haaaaa ha ha ha ha ha ha haha haha ha ha!!!!!! Another thigh-slapper from Therapeutic Anthony!
Sydney journalist wants to know when unvaccinated people will be banned from supermarkets

US CDC advice on withdrawal of Covid PCR test accreditation - it can't differentiate between Covid and the flu

UPDATE

 
In Australia we have 83 COVID testing kits approved. 10 of those use RT-PCR. https://www.tga.gov.au/covid-19-test-kits-included-artg-legal-supply-australia If those 10 brands of COVID testing kits are taken offline then our fallback position is well and truly covered. As Dr Brett Sutton said in an earlier video, if a person's swab initially comes up as COVID positive even if the PCR testing method is used then the specimen "goes through a quality assurance process to make sure that it is absolutely and unequivocally a positive test." No need to panic, no need to muddy the waters.
Reply | Edit | 37 minutes ago on US CDC advice on wi…
 

Screen Shot 2021-07-27 at 1.19.47 pm

After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.

Visit the FDA website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page.

In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.

Opt in to receive updates from the CDC Laboratory Outreach Communication System (LOCS).

Online resources:

If you have any questions, please contact us at LOCS@cdc.gov.

Thank you,

The Laboratory Outreach Communication System

Laboratory Outreach Communication System (LOCS) | Division of Laboratory Systems (DLS)

Center for Surveillance, Epidemiology, and Laboratory Services (CSELS)

Centers for Disease Control and Prevention (CDC)

LOCS@cdc.gov

www.cdc.gov/csels/dls/locs

Comments